Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

argenx

Biotech & Life Sciences · Ghent, Belgium · Founded 2008 · IPO 2014 Decacorn

Platform for antibody lead choice that supports the discovery of human antibody therapeutics

Valuation
$44B
Market cap · May/2026
Revenue
$4.15B
Latest reported FY
EBITDA
$1.85B
Latest reported FY

Investors

11 investors on argenx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
Erasmus MC Biomedical Fund
Omnes Capital
Thuja Capital
Forbion Capital Partners
KBC
MVM Life Science Partners
BioGeneration Ventures
Series B+ 4 investors entered at this stage
Seventure Partners
EQT Life Sciences
OrbiMed
PMV

Global footprint

Where argenx has talent and traffic

AI talent share
0.5% of workforce is AI talent
(10 of 2,173 staff)
Core AI00%
Other AI100.46%
Non-AI workforce2,16399.54%
Workforce by country
28 countries with
team presence
🇺🇸 United States40.5%
🇧🇪 Belgium34.9%
🇬🇧 United Kingdom4.3%
🇨🇭 Switzerland2.6%
🇩🇪 Germany2.5%
Top 5 of 28 shown
Web traffic by country
59K monthly visits
across markets
🇺🇸 United States24.1%
🇧🇪 Belgium15.4%
🇩🇰 Denmark13.7%
🇦🇺 Australia5.6%
🇬🇧 United Kingdom4.9%
Top 5 markets shown

Patent intelligence

$275M patent portfolio · 101 active families

Estimated portfolio value
$275M
0.62% of market cap · 2.8× smaller than top peer BioNTech ($780M)
101 active patent families
Where argenx innovates Molecular biologyAntagonistAntiendomysial antibodiesAntigen bindingAntigen Binding Fragment

Where argenx concentrates vs peers

Each axis is a top-10 topic across argenx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

argenx's 3 investments and acquisitions.

Every disclosed deal where argenx appeared as a backer or acquirer, 2019–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across argenx's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where argenx deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        argenx's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about argenx

        An AI-synthesized read of the highest-engagement posts about argenx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See argenx on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.